Azvudine - Wikipedia
网页Azvudine is an antiviral drug which acts as a reverse transcriptase inhibitor. [3] It was discovered for the treatment of hepatitis C [4] and has since been investigated for use against other viral diseases such as AIDS and COVID-19, [2] [5] for which it was granted conditional approval in China. [6] [7] Azvudine was first discovered in 2007. [8]
Oral Azvudine for hospitalised patients with COVID-19 and pre …
网页A randomized, open-label, controlled clinical trial of Azvudine tablets in the treatment of mild and common COVID-19, a pilot study
阿兹夫定 - 百度百科
网页阿兹夫定（Azvudine），又称阿滋福啶，由 常俊标 教授发明， 河南真实生物科技有限公司 、 郑州大学 、 河南师范大学 、 河南省科学院高新技术研究中心 共同研发 [7]。. 它是一种艾滋病毒逆转录酶（RT）抑制剂，属世界先进、国内首创的新一代治疗艾滋病药物 ...
Efficacy and safety evaluation of Azvudine in the prospective …
网页2023年8月24日 · Azvudine (FNC) is a synthetic nucleoside analog used to treat adult patients living with human immunodeficiency virus-1 (HIV-1) infection with high viral load. After phosphorylation, Azvudine inhibits RNA-dependent RNA polymerase, leading to the discontinuation of RNA chain synthesis in viruses.
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in …
网页2021年12月6日 · Azvudine (FNC) is a nucleoside analog that inhibits HIV-1 RNA-dependent RNA polymerase (RdRp). Recently, we discovered FNC an agent against SARS-CoV-2, and have taken it into Phase III trial for...
Efficacy and safety of azvudine in patients with COVID-19: A …
网页2023年9月14日 · Azvudine can significantly increase the proportion of patients with improved clinical symptoms of COVID-19 within 5 days of treatment and achieve excellent clinical results. In terms of inhibiting COVID-19, it can inhibit the activity of COVID-19 and increase the proportion of PT-PCR negativity.
A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets ...
网页2020年8月13日 · This pilot study is a randomized, open, controlled clinical trial to evaluate the efficacy and safety of azvudine tablets in the treatment of COVID‐19. Our trial found that azvudine may shorten the time of nucleic acid negativity conversion of persistent mild and common COVID‐19 patient versus standard antiviral therapy.
网页Azvudine inhibited SARS-CoV-2 with the virus clearance time of about 5 days. Compared with the control group, the viral load of the Azvudine group decreased by an average of 1.56 log10 on the fifth day of medication. Azvudine was also effective against virus var-iants (Alpha, Beta, Delta, and Omicron). In terms of the safety, Azvudine (5 mg
Azvudine (FNC): a promising clinical candidate for COVID-19
网页2020年10月10日 · To evaluate the efficacy and safety of FNC in patients with mild and common COVID-19, we recently conducted a randomized, open-label, controlled clinical trial of FNC tablets in China ...
网页A very recent work published in Advanced Science by our group reveals that 2′-deoxy-2′-β-fluoro-4′-azidocytidine (Azvudine, FNC), a clinical candidate originally developed for HIV treatment, has...